We have a drug shortage problem—here’s how we can solve it | Caroline Schober | TEDxMedUniGraz

Europe’s Pharmaceutical Vulnerability & The Path to Resilience

Key Concepts:

• Active Pharmaceutical Ingredients (APIs): The part of a medicine that produces its effect.
• Continuous Manufacturing: A modern pharmaceutical production method offering speed and flexibility compared to traditional batch processing.
• Critical Medicines Act (EU): Legislation aimed at bolstering local medicine production and creating strategic stockpiles.
• Resilience vs. Efficiency: The trade-off between cost-effectiveness and the ability to withstand disruptions in the supply chain.
• Pharmaceutical Recycling: Recovering and repurposing ingredients from expired or failed pharmaceutical batches.
• Strategic Stockpiling: Maintaining reserves of essential medicines to mitigate shortages.

I. The Current Crisis: A Fragile Pharmaceutical Landscape

The video highlights a critical vulnerability in the European pharmaceutical supply chain. Currently, approximately 70% of Active Pharmaceutical Ingredients (APIs) originate from China and India, with around 80% of the chemical precursors for those APIs also sourced from these two countries. This concentration creates significant risk, exposing Europe to disruptions from events like factory fires, natural disasters, pandemics, and geopolitical tensions (trade wars). The speaker emphasizes that this isn’t about luxury treatments, but about essential medicines – antibiotics, painkillers, blood pressure medication, and insulin – the absence of which directly leads to suffering and death. Austria, a highly developed nation, currently experiences shortages of nearly 500 medicines, a situation mirrored across Europe, the US, and other regions.

The speaker points to the COVID-19 pandemic as a stark example of this fragility, demonstrating how prioritizing efficiency over resilience resulted in supply chain collapse when borders closed and local production was favored by exporting nations.

II. The Cost of Efficiency & The Case for Local Production

The economic drivers behind this reliance on foreign production are explored. Manufacturing in Europe is 20-50% more expensive due to higher labor, energy, and regulatory costs (environmental and work safety standards). This incentivizes companies to seek cheaper production elsewhere.

A compelling example is Austria’s sole fully integrated penicillin production plant, capable of meeting all of Europe’s needs. However, it requires €50 million in EU and Austrian government funding to remain competitive against Asian producers. This illustrates the financial burden of maintaining local production in the face of global cost pressures. The speaker notes the irony of inexpensive over-the-counter medications masking the complex and vulnerable supply chains behind them.

III. The Limitations of Traditional Approaches: Stockpiling & Reporting

The EU’s response, the Critical Medicines Act, aims to address the issue through local production incentives and strategic stockpiling. However, the speaker argues that traditional stockpiling is problematic. Medicines have limited shelf lives (typically 2-3 years), and the majority of a pill’s composition consists of inactive ingredients (fillers, binders, etc.) and packaging, requiring massive and constantly rotating warehouse space, leading to significant waste of expired medication. This would exacerbate existing shortages rather than alleviate them.

The current reporting system for shortages is also flawed. More than half of shortages are reported after they occur, hindering proactive mitigation efforts. The lack of standardized reporting definitions across EU member states further complicates the situation.

IV. A Paradigm Shift: Continuous Manufacturing & Ingredient Storage

The speaker proposes a radical shift in strategy: instead of stockpiling finished products, focus on storing pure, compact APIs in ultra-long-storage containers (20-30 years stability). This would allow for on-demand local production using modern manufacturing techniques.

Continuous Manufacturing is presented as a key solution. Compared to traditional batch production (6-12 months, plus 6-18 months for new products), continuous manufacturing, utilizing stored ingredients, could be operational within 1-2 weeks and produce 10 million tablets per week. Continuous manufacturing facilities are significantly smaller and cheaper to build (approximately €50 million versus hundreds of millions for traditional plants) and are the size of a basketball court. Importantly, this technology is not theoretical; much of it was developed in Austria.

V. Pharmaceutical Recycling: Turning Waste into Resource

The speaker highlights the massive amount of pharmaceutical ingredients wasted through expired medicines and failed production batches – often incinerated as toxic waste despite containing valuable compounds, some worth more than gold per gram. Recycling these ingredients, turning expired antibiotics into raw materials for new ones, offers a sustainable solution to address shortages and reduce waste.

The challenges to pharmaceutical recycling include:

• Technological Complexity: Extracting pure ingredients from complex tablets. (Initial results are promising.)
• Economic Viability: Recycling is not cost-effective for all compounds, but is crucial for expensive drugs and antibiotics facing shortages.
• Regulatory Hurdles: The need for a streamlined regulatory framework balancing safety and sustainability, particularly within the EU.

VI. The Political & Economic Barriers to Change

The speaker argues that the primary obstacle isn’t technological, but political and economic. Pharmaceutical companies prioritize profit, buying low and selling high, and are not legally obligated to ensure supply chain security. Governments and insurance systems prioritize price over resilience, creating a system that incentivizes vulnerability.

The speaker draws a parallel to energy and military security, arguing that medicine safety deserves the same national priority and investment. With an annual healthcare expenditure of €1.6 trillion in the EU (and over 10% of GDP in Austria), even a small investment in robust supply chains could eliminate medicine shortages.

VII. A Vision for the Future: Local Resilience & Fundamental Access

The speaker concludes with a vision for a future where healthcare is no longer dependent on global supply chain disruptions. This future relies on:

• Government investment in research and innovative manufacturing.
• Public procurement policies that prioritize resilience and sustainability.
• Regulatory frameworks that embrace innovation.
• EU cooperation to avoid fragmented national approaches.

The speaker envisions a scenario 10 years from now where a child in Vienna receives a locally produced antibiotic promptly, a cancer patient in Berlin receives uninterrupted chemotherapy, and a surgeon in Paris operates with confidence knowing all necessary medications are available. This future, the speaker emphasizes, is achievable with political will, recognizing access to medicine as a fundamental right, not a privilege.

Notable Quote:

“When medicines aren't there, people suffer and people die. It's as brutally simple as that.” – The speaker, emphasizing the human cost of pharmaceutical shortages.

Data & Statistics:

• 70% of APIs come from China and India.
• 80% of chemical precursors for APIs come from China and India.
• Austria hosts Europe’s only fully integrated penicillin production plant.
• €50 million in EU/Austrian funding supports the penicillin plant.
• Traditional batch production takes 6-12 months + 6-18 months for new products.
• Continuous manufacturing could be operational in 1-2 weeks.
• Continuous manufacturing facilities cost ~€50 million.
• EU healthcare expenditure: €1.6 trillion annually.